Two Years Follow-Up of Patients with Abnormal Uterine Bleeding after Insertion of the Levonorgestrel-Releasing Intrauterine System


Cim N., SOYSAL S., Sayan S., YILDIZHAN B., Karaman E., Cetin O., ...More

GYNECOLOGIC AND OBSTETRIC INVESTIGATION, vol.83, no.6, pp.569-575, 2018 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 83 Issue: 6
  • Publication Date: 2018
  • Doi Number: 10.1159/000480012
  • Journal Name: GYNECOLOGIC AND OBSTETRIC INVESTIGATION
  • Journal Indexes: Science Citation Index Expanded, Scopus
  • Page Numbers: pp.569-575
  • Keywords: Levonorgestrel, LNG-IUS, Heavy menstrual bleeding, Uterine volume, Pulsatile index, Endometrial biopsy, OVARIAN-FUNCTION, MENORRHAGIA, DEVICE, ENDOMETRIUM, THERAPY, WOMEN, IUD

Abstract

Aim: To evaluate the efficacy and safety of levonorgestrel-releasing intrauterine system (LNG-IUS) in the long-term treatment of heavy menstrual blood loss in women unrelated to intrauterine pathology. Methods: One hundred and six parous women aged 33-48 years with recurrent heavy menstrual bleeding (HMB) participated in this study. The women were followed up for 24 months and were assessed for intensity of bleeding both for pre- and post-insertion periods. An LNG-IUS was inserted in each patient within 7 days of the start of menstrual flow. The women were followed up at 1, 3, 6, 12, 18, and 24 months following the insertion of the intrauterine device. Results: One hundred and two women completed the follow-up period and had a significant reduction in the amount of menstrual blood loss. The LNG-IUS was well tolerated by all women. Pre-treatment of the use of the LNG-IUS, endometrial biopsy patterns for irregular proliferative endometrium and for atypical simple hyperplasia were 34/106 (32.08%) and 61/106 (57.55%) respectively and after treatment no abnormal pathologic findings were determined (p < 0.001). Conclusion: Our findings indicate that the LNG-IUS is effective for significantly reducing the amount of menstrual blood loss in women with HMB. (c) 2017 S. Karger AG, Basel